Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressantcodeine, morphine, oxycodone +4 morecodeine, morphine, oxycodone, hydrocodone, heroin, fentanyl, other mu-opioid agonists show less
Tramadol
Tramadol is a synthetic opioid of the aminocyclohexanol class. It is structurally related to codeine, but unlike most opioids, it also acts as an antidepressant-like compound. It activates opioid receptors while raising serotonin and norepinephrine levels, producing pain suppression alongside mood elevation and subtle alertness.[1][2]
Tramadol is a synthetic opioid of the aminocyclohexanol class. It is structurally related to codeine, distinguished by its dual mechanism and weaker opioid activity. Tramadol is a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor, producing its effects by combining mild opioid pain suppression with monoamine modulation.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Depressantcodeine, morphine, oxycodone +4 morecodeine, morphine, oxycodone, hydrocodone, heroin, fentanyl, other mu-opioid agonists show less
Grünenthal GmbH synthesized tramadol in 1962, seeking a painkiller with less respiratory depression than morphine.[3] It reached the US market in the mid-1990s and stayed federally unscheduled for nearly two decades — longer than almost any other opioid analgesic. The DEA classified it as Schedule IV in 2014,[4] and non-medical use is now a major public health problem in parts of the Middle East and sub-Saharan Africa.
Subjective effects include pain relief, mood elevation, mild sedation, anxiolysis, and a stimulant-like wakefulness and sociability uncommon among opioids. The experience blends a muted opioid warmth with a subtle alertness — a hybrid character shaped heavily by how each person's liver processes the drug. Nausea, dizziness, sweating, and constipation are characteristic unwanted effects.
Tramadol produces physical dependence; its main dangers are seizures, serotonin overload when combined with antidepressants, and breathing suppression in fast metabolizers.[5][6] The same dose can be barely perceptible in one person and dangerously potent in another; withdrawal adds hallucinations and sensory disturbances on top of standard opioid cessation.[7] Decades of clinical use underpin the evidence base, though the seizure mechanism and tolerance kinetics remain uncharacterized.[8]
History[edit]
Discovery
Tramadol was synthesized in 1962 by Grünenthal GmbH in Germany, designed as a painkiller with less respiratory depression and lower dependence risk than morphine.[3] It was first marketed as Tramal in Germany in 1977, then authorized in the UK in 1994 and the US in the mid-1990s.
Clinical Significance
Tramadol was positioned as a safer alternative to conventional opioids — its weak opioid binding and dual mechanism were expected to limit both respiratory depression and abuse potential. This kept it federally unscheduled in the United States for nearly two decades after approval, a status unusual among opioid analgesics. A 2025 review of 58 clinical trials confirmed efficacy for chronic pain, though not consistently superior to other analgesics.[9]
Scheduling and Modern Use
As misuse data accumulated, controls tightened: the US DEA classified tramadol as Schedule IV in 2014,[4] the UK moved it to Class C the same year,[10] and Canada added it to Schedule I in 2021.[3] Non-medical use has become a major public health crisis in Iran, Egypt, and sub-Saharan Africa, where it is taken for stimulant and euphoric effects at doses far above therapeutic ranges.[11][12] Despite this, tramadol remains outside the UN international narcotic control framework.[13]
The brand name Tramal became synonymous with tramadol across much of continental Europe. In 2013, tramadol was detected in the roots of Nauclea latifolia in Cameroon — initially described as the first synthetic drug found in a natural source.[14] Later research suggested environmental contamination from veterinary tramadol may explain the finding, and the question remains unresolved.
Chemistry[edit]
Structural Class
Tramadol is a synthetic aminocyclohexanol — a codeine structural analog built on a cyclohexane ring scaffold.[1] Its molecular formula is C₁₆H₂₅NO₂ (molecular weight 263.37 g/mol).
Key Metabolite
The liver enzyme CYP2D6 converts tramadol into an active metabolite called O-desmethyltramadol (M1).[2] M1 is far more potent at opioid receptors than tramadol itself — making this conversion the key step that determines how much opioid effect any given dose produces, and why the same dose can feel very different between people.
Pharmacology[edit]
Mechanism of Action
Tramadol works through two complementary pathways.[1][2] It is a weak opioid — but most of its opioid activity comes from M1, its active metabolite, which is over 100 times more potent at opioid receptors than tramadol itself.[2] It also raises serotonin and norepinephrine by blocking their reuptake, strengthening the brain's own pain-dampening signals.[1]
Pharmacokinetics
Oral tramadol is well absorbed, reaching about 70% bioavailability.[1][15] The parent compound remains active for roughly 5 hours; M1 persists for about 9 hours.[1] CYP2D6 drives M1 production — drugs that inhibit this enzyme reduce opioid pain suppression while raising tramadol plasma levels and serotonergic activity.[16][17]
Tramadol also triggers dopamine release in the brain's reward system through its opioid component.[2] This reward signal is weaker than with classical opioids, but it still contributes to abuse potential.
Neuroscience[edit]
Where It Acts
M1 — tramadol's active metabolite — engages opioid receptors along the brain's main pain-suppression pathway, running from the midbrain down through the brainstem to the spinal cord.[1] Tramadol's serotonin-norepinephrine component works in parallel, reinforcing a separate descending pathway that reduces pain signals at the spinal level.[1] Naloxone can partially block the first pathway but not the second.
Reward, Seizures, and Variability
Tramadol activates the brain's reward circuitry through dopamine release, driven by its opioid component.[2] This reward signal is weaker than with classical opioids, confirmed by lower drug-liking scores in clinical studies.[18] CYP2D6 genetics transform a single dose into radically different drug exposures across individuals.[6]
At analgesic doses, tramadol can suppress seizures; at high doses, it triggers them through a mechanism independent of serotonin.[8][5]
Tramadol withdrawal includes unusual symptoms — hallucinations, strange sensory phenomena, excessive mucus production — not seen with classical opioid cessation.[7] The brain basis of this dual withdrawal syndrome is uncharacterized. Whether the seizure risk comes from tramadol itself or from M1 has not been determined.[5]
Subjective Effects[edit]
Tramadol blends a muted opioid warmth with a stimulant-like alertness and sociability not found in conventional opioids. At lower doses, mood elevation and wakefulness dominate; sedation and analgesia come forward at higher amounts. Individual response varies more than with most opioids.
Compared to codeine, tramadol offers more noticeable mood enhancement and mild stimulation, though both depend on CYP2D6 conversion for opioid effect. Compared to morphine or oxycodone, tramadol's euphoria is substantially milder and sedation less pronounced, with consistently lower drug-liking scores in clinical assessments.[18]
Synthesized in 1962 by Grünenthal GmbH during a search for analgesics with reduced respiratory depression,[3] tramadol was first marketed in Germany in 1977 and reached the United States in the mid-1990s. It remained federally unscheduled for nearly two decades before the DEA classified it as Schedule IV in 2014.[4] Non-medical use has become a significant public health concern in parts of the Middle East and sub-Saharan Africa, while regulatory controls continue tightening worldwide.
Subjective effects include analgesia, anxiolysis, mood elevation, and mild sedation. The experience combines a muted opioid warmth with subtle stimulant-like alertness and sociability — a hybrid character uncommon among opioids, shaped heavily by individual CYP2D6 metabolism. Nausea, dizziness, constipation, and sweating are characteristic unsought effects.
Tramadol produces physical dependence with prolonged use, and its toxicity is defined by seizure risk, serotonin syndrome with serotonergic drugs,[5] and respiratory depression in ultrarapid CYP2D6 metabolizers.[6] Its prodrug pharmacology means the same dose produces negligible opioid effect in one person and opioid toxicity in another; withdrawal adds atypical serotonergic features to classical opioid cessation.[7] Decades of clinical use underpin the evidence base, though seizure mechanisms and tolerance kinetics remain uncharacterized.[8]
History[edit]
Discovery
Tramadol was synthesized in 1962 by Grünenthal GmbH in Aachen, West Germany, during a program seeking analgesics with reduced respiratory depression and lower abuse liability than morphine.[3] The compound was patented in 1972 and first marketed in Germany in 1977 under the brand name Tramal.[3] UK authorization followed in 1994, and US approval came in the mid-1990s.
Clinical Significance
Tramadol was positioned as a safer alternative to conventional opioids — its weak μ-opioid binding and dual mechanism were expected to limit both respiratory depression and abuse potential. This perception kept it federally unscheduled in the United States for nearly two decades after approval, a status virtually unique among opioid analgesics. A 2025 review of 58 clinical trials confirmed efficacy for chronic pain, though not consistently superior to comparators.[9]
Scheduling and Modern Use
As post-marketing misuse data accumulated, controls tightened: the US DEA classified tramadol as Schedule IV in August 2014,[4] the UK moved it to Class C the same year,[10] and Canada added it to Schedule I in 2021.[3] Non-medical use has become a major public health concern in Iran, Egypt, and sub-Saharan Africa, where tramadol is taken for stimulant and euphoric effects at doses far exceeding therapeutic ranges.[11][12] Despite this, tramadol remains outside international narcotic control under the UN 1961 and 1971 conventions.[13]
The brand name Tramal became synonymous with tramadol across much of continental Europe. In 2013, tramadol was detected in the roots of Nauclea latifolia in Cameroon at concentrations up to 3.9% of dried bark — initially described as the first synthetic drug found in a natural source.[14] Subsequent research suggested this may reflect environmental contamination from veterinary tramadol rather than plant biosynthesis, and the question remains unresolved.
Chemistry[edit]
Structural Class
Tramadol is a synthetic aminocyclohexanol — structurally a codeine structural analog built on the 4-phenylpiperidine scaffold.[1] Its molecular core is a cyclohexane ring bearing a tertiary hydroxyl group, a dimethylaminomethyl side chain, and a 3-methoxyphenyl substituent. This arrangement gives tramadol structural resemblance to both codeine and the broader synthetic opioid series.
| Molecular formula | C₁₆H₂₅NO₂ |
| Molecular weight | 263.37 g/mol |
Stereochemistry
Tramadol contains two chirality centers at C-1 and C-2 of the cyclohexane ring. The pharmaceutical form is the cis-(1R,2R)/(1S,2S) racemic mixture. The enantiomers have distinct pharmacological profiles: (+)-tramadol preferentially inhibits serotonin reuptake and has higher opioid receptor affinity, while (−)-tramadol preferentially inhibits norepinephrine reuptake.[2][1] The trans diastereomers are not used therapeutically.
Key Metabolite
The 3-methoxyphenyl group is the site of CYP2D6-mediated O-demethylation, which converts tramadol to O-desmethyltramadol (M1).[2] M1 is substantially more active at the μ-opioid than the parent compound, making this metabolic step the rate-limiting determinant of tramadol's opioid activity and the basis of its pharmacogenomic variability.
Pharmacology[edit]
Mechanism of Action
Tramadol produces analgesia through two complementary mechanisms[1][2]:
Weak mu-opioid receptor agonism. Tramadol itself binds the μ-opioid with very low affinity — roughly 6,000-fold weaker than morphine.[1] The primary opioid activity comes from its active metabolite M1, produced by liver enzyme CYP2D6. M1 binds the mu-opioid receptor more than 100-fold more strongly than the parent compound.[2] Naloxone only partially reverses tramadol's analgesic effect, confirming that opioid agonism alone does not account for its pain suppression.
Serotonin-norepinephrine reuptake inhibition. Tramadol blocks reuptake of both serotonin and norepinephrine, enhancing descending pain inhibition at the spinal level.[1] This monoaminergic component is responsible for tramadol's atypical properties within the opioid class — including its capacity to cause serotonin syndrome and its off-label use for premature ejaculation.[15]
Enantioselective Pharmacology
Tramadol is administered as a racemic mixture with complementary enantiomers[2][1]:
- (+)-Tramadol: Preferentially inhibits serotonin reuptake; higher mu-opioid affinity.
- (−)-Tramadol: Preferentially inhibits norepinephrine reuptake; lower mu-opioid affinity.
The racemic combination produces analgesic synergy that neither enantiomer achieves alone.
Pharmacokinetics
Oral bioavailability is 68–71%,[1][16] with peak plasma levels reached in approximately 1–2 hours.[1] The parent compound has a half-life of roughly 5 hours; the active metabolite M1 persists longer at approximately 9 hours.[1] Plasma concentrations above 100 ng/mL are needed for analgesia.[17]
Tramadol is metabolized primarily by CYP2D6, with contributions from CYP2B6 and CYP3A4.[18][19] Enzyme inducers such as rifampicin markedly decrease tramadol exposure.[19] Extended-release formulations achieve equivalent total exposure to immediate-release dosing with lower peak levels, reaching steady state within 48 hours.[17]
M1 also inhibits muscarinic receptors,[20] and tramadol enhances dopamine release in reward-associated brain regions via an opioid-dependent mechanism[2] — a property that may contribute to its abuse potential.
Neuroscience[edit]
Where It Acts
The active metabolite M1 acts as a μ-opioid agonist within the descending pain pathway — periaqueductal gray through rostral ventromedial medulla to the spinal cord — suppressing ascending pain signals.[1] This mechanism is partially reversible by naloxone, confirming engagement of the endogenous opioid system.
Simultaneously, tramadol's serotonin-norepinephrine reuptake inhibitor strengthens a parallel descending inhibitory pathway at the spinal level.[1] This component provides analgesia through a non-opioid mechanism that naloxone cannot reverse, operating via distinct neural circuitry from classical opioids.
Reward, Seizures, and Variability
Tramadol activates the brain's reward circuitry through dopamine release in the mesolimbic pathway, driven by its opioid component.[2] The metabolite M1, but not the parent compound at low doses, sustains conditioned place preference in animal models — a standard marker of rewarding properties.[21] This weaker reward signal, compared to classical opioids, aligns with tramadol's lower drug-liking scores in clinical assessments.[22]
Paradoxically, tramadol shows anticonvulsant effects at analgesic doses but triggers seizures at supratherapeutic doses,[8] through a mechanism independent of brain serotonin levels.[5] CYP2D6 genetic polymorphism transforms a single administered dose into radically different pharmacological exposures across individuals.[6]
Tramadol withdrawal includes atypical features — hallucinations, unusual sensory phenomena, excessive mucus production — not seen with classical opioid cessation.[7] The neural basis of this dual withdrawal syndrome is uncharacterized. The specific mechanism by which tramadol lowers seizure threshold remains unknown; whether the parent compound or M1 is the primary proconvulsant has not been determined.[5]
Subjective Effects[edit]
Tramadol's subjective character reflects its dual mechanism — weak opioid agonism layered with serotonin-norepinephrine reuptake inhibitor produces a hybrid experience qualitatively distinct from classical opioids. Opioid warmth and anxiolysis coexist with a subtle stimulant-like wakefulness and sociability uncommon in the class. At lower doses, mood elevation and alertness predominate; at higher doses, opioid sedation and analgesia become more prominent. Individual response is unusually variable — CYP2D6 metabolism determines how much active opioid metabolite each person produces, so the same dose may feel barely perceptible to one person and strongly sedating to another.
Compared to codeine, tramadol offers a more complex profile with noticeable mood enhancement and mild stimulation, though both are weak opioids dependent on CYP2D6 activation. Compared to morphine or oxycodone, tramadol's euphoria is substantially milder and its sedation less pronounced, with consistently lower drug-liking scores in clinical assessments.[22]
Effect Grid
At common doses (100–200 mg oral), the dual pharmacological profile becomes clearly perceptible. Moderate analgesia is accompanied by noticeable mood elevation and anxiolysis. Euphoria is mild compared to classical opioids but present, particularly in opioid-naive individuals. The SNRI component contributes a subtle stimulant quality — wakefulness, sociability, and mild empathy enhancement coexist with opioid-type relaxation.
Physically, nausea becomes more likely (particularly at the upper end or with rapid-loading doses), along with constipation, mild sweating, and pupil constriction. Itching (pruritus) may occur. Some sedation develops, though less pronounced than with equipotent doses of classical opioids.
Functional impairment is moderate. Duration of subjective effects is approximately 4–6 hours, with residual sedation and mood effects persisting beyond this window.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Visual acuity suppression · Visual haze / noise · Visual processing suppression
Constipation · Body high · Dizziness · Sedation · Tactile euphoria · Spontaneous body sensations · Bodily heaviness · Dry mouth · Muscle relaxation · Physical fatigue · Sexual arousal suppression · Appetite suppression · Restlessness · Headache · Excessive sweating · Motor control impairment · Stimulation · Tingling / electric sensations · Yawning · Dehydration sensation · Wakefulness · Brain zaps · Heart rate perception changes · Insomnia · Trembling · Vomiting · Watery eyes · Bodily lightness · Bruxism · Diarrhea · Muscle tension · Nystagmus (eye wobbles) · Pain enhancement · Vasoconstriction · Bodily dissociation
Sedation · Tactile euphoria · Spontaneous body sensations · Bodily heaviness · Dry mouth · Muscle relaxation · Physical fatigue · Sexual arousal suppression · Appetite suppression · Restlessness · Headache · Excessive sweating · Stimulation · Tingling / electric sensations · Yawning · Dehydration sensation · Wakefulness · Brain zaps · Heart rate perception changes · Insomnia · Trembling · Vomiting · Watery eyes · Bodily lightness · Bruxism · Diarrhea · Muscle tension · Nystagmus (eye wobbles) · Pain enhancement · Vasoconstriction · Bodily dissociation
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Memory suppression · Memory fragmentation · Aesthetic enhancement · Confusion · Immersion enhancement · Language suppression · Motivation suppression · Suggestibility enhancement · Thought disorganization · Motivation enhancement · Humor enhancement · Thought acceleration · Cognitive dysphoria · Introspection enhancement · Novelty enhancement · Openness enhancement · Focus enhancement · Amnesia
Information processing suppression · Memory suppression · Memory fragmentation · Aesthetic enhancement · Confusion · Immersion enhancement · Language suppression · Motivation suppression · Thought disorganization · Motivation enhancement · Humor enhancement · Thought acceleration · Cognitive dysphoria · Introspection enhancement · Novelty enhancement · Openness enhancement · Focus enhancement · Amnesia
Empathy enhancement · Anxiety · Anhedonia · Dysphoria · Emotional enhancement · Emotional lability · Emotional suppression · Empathy suppression
Emotional enhancement · Emotional lability · Emotional suppression · Empathy suppression
Social disconnection · Sociability enhancement · Depersonalization · Derealization · Sociability suppression · Social connection · Trust enhancement · Communication enhancement · Flow state · Cognitive disconnection
Sociability suppression · Social connection · Trust enhancement · Communication enhancement · Flow state · Cognitive disconnection
Timeline
First perceptible effects emerge as mild warmth, subtle mood shift, or faint dulling of pain. Onset timing varies significantly with CYP2D6 phenotype and stomach contents.
Analgesia and mood elevation build gradually. The SNRI component may produce a subtle energizing quality alongside emerging opioid relaxation. Mild nausea may appear.
Maximum analgesia and mood effects. The dual opioid-SNRI profile is most distinct at peak: warmth and sedation layered with mild stimulation and sociability. Nausea, if present, is most prominent during this phase.
Analgesic effects remain above threshold but subjective intensity diminishes. Sedation may increase as the stimulant-like SNRI component fades relative to opioid effects. M1 metabolite (t½ ~9 hours) sustains residual opioid activity.
Gradual return to baseline. Analgesia fades. Mild fatigue, emotional flatness, or subtle irritability may emerge as monoamine levels normalize.
Residual sedation, mild constipation, and subtle mood effects may persist for several hours due to M1's extended half-life (~9 hours). Psychomotor impairment may outlast subjective effects.
⚠ Do not drive or operate heavy machinery for at least 12 hours after dosing, as residual M1 activity may impair reaction time and judgment beyond the subjective experience window.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- codeine · morphine · oxycodone
Toxicity
Tramadol has lower acute toxicity than classical opioids at therapeutic doses,[9] but three dose-limiting risks narrow its safety margin.
Seizures
Tramadol lowers the seizure threshold in a dose-dependent way.[8] Risk is significantly elevated in people with epilepsy or other conditions that already reduce seizure threshold. The mechanism is independent of serotonin levels.[5]
Respiratory Depression
Tramadol suppresses breathing — less severely than morphine at equivalent doses, but clinically significant in overdose.[1] Combining it with benzodiazepines carries a specific paradox: benzodiazepines block tramadol-induced seizures but worsen respiratory depression.[5]
Serotonin Syndrome
Combining tramadol with drugs that raise serotonin can trigger a life-threatening state involving fever, muscle rigidity, rapid heartbeat, and seizures. Documented combinations include SNRIs,[21] gabapentin,[22] MAOIs, tricyclic antidepressants, SSRIs, and ziprasidone.[23] This reaction has also occurred from tramadol alone in a pediatric patient with no concurrent serotonergic drugs.[24]
Of common opioids, only tramadol and meperidine trigger this response — morphine does not.[25]
Hypoglycemia
Analysis of over 12 million FDA adverse event reports found significantly more low blood sugar with tramadol than with other opioids.[19] The mechanism is unknown.[20]
Cardiovascular Effects
Tramadol's serotonin- and norepinephrine-raising mechanism raises theoretical concerns for vasoconstriction and cardiovascular events.[26] Controlled data are limited.
CYP2D6 Ultrarapid Metabolizer Toxicity
In people who break down tramadol very fast (CYP2D6 ultrarapid metabolizers), standard doses produce excessive M1, causing opioid toxicity — slowed breathing, extreme sedation, and confusion.[6] At least one pediatric death has been reported. FDA labeling now contraindicates tramadol in known ultrarapid metabolizers.[6]
Pediatric Toxicity
Tramadol is contraindicated in children under 12 and in all patients under 18 for post-tonsillectomy or adenoidectomy pain. Life-threatening breathing suppression and death have occurred in pediatric patients.[6]
Psychological Risks
Psychological dependence is moderate compared to stronger opioids,[18] but significant misuse is documented in Iran, Egypt, and sub-Saharan Africa.[11][12] The SNRI component produces mood disturbance on discontinuation that goes beyond typical opioid withdrawal.[7]
Tolerance & Dependence
Physical dependence develops with regular use.[12] Tramadol withdrawal is a dual syndrome[7]: classic opioid cessation symptoms (anxiety, sweating, insomnia, muscle pain, gastrointestinal distress) combined with atypical features (hallucinations, unusual sensory phenomena, excessive mucus production) not seen with other opioids.
Tolerance develops with prolonged use, particularly at high doses. How quickly it builds and how long it takes to reset have not been characterized.citation needed
Drug Interactions
Serotonin syndrome. Combining tramadol with any serotonin-raising drug risks a life-threatening state — fever, rigid muscles, rapid heartbeat, seizures. Documented combinations include SNRIs,[21][27] gabapentin,[22] ziprasidone,[23] MAOIs, tricyclics, SSRIs, and serotonin precursors (5-HTP, tryptophan). Of common opioids, only tramadol and meperidine carry this risk.[25]
CNS depressant synergy. Combining tramadol with benzodiazepines, alcohol, other opioids, or GHB produces additive breathing suppression. The tramadol-benzodiazepine combination carries a specific paradox: benzodiazepines block tramadol-induced seizures but worsen respiratory depression.[5]
CYP2D6 inhibitors. Paroxetine, fluoxetine, and duloxetine reduce M1 formation — weakening opioid pain suppression — while raising tramadol plasma levels and serotonergic activity.[28]
Seizure threshold drugs. Stimulants such as amphetamine, cocaine, and MDMA also lower seizure threshold. Combined use may trigger seizures, compounded by cardiovascular strain.
Contraindications
10 knownAbsolute:
- MAOIs (current or within 14 days): Severe or fatal serotonin syndrome may result.[1]
- CYP2D6 ultrarapid metabolizer status: Standard doses cause opioid toxicity.[6]
- Children under 12: Life-threatening breathing suppression and death reported.[6]
- Post-tonsillectomy/adenoidectomy in patients under 18: Specific FDA contraindication.[6]
Relative:
- Epilepsy or lowered seizure threshold: Tramadol's proconvulsant activity makes it inappropriate.[8]
- Concurrent serotonergic medication: SSRIs, SNRIs, tricyclics, triptans, and serotonin precursors increase serotonin syndrome risk.[21][22]
- Severe liver impairment: Altered drug and metabolite exposure unpredictably changes risk.
- Pregnancy: Associated with neonatal withdrawal syndrome.[29]
- Breastfeeding in CYP2D6 ultrarapid metabolizer mothers: Excess M1 in breast milk poses risk to nursing infants.[30]
- Concurrent CNS depressants: Alcohol, benzodiazepines, other opioids — enhanced breathing suppression.[5]
Harm Reduction[edit]
Forms & Identification
Tramadol circulates almost exclusively as pharmaceutical tablets and capsules in both immediate-release and extended-release formulations. Prescription tramadol from licensed pharmacies carries lower identification risk than most illicitly sourced substances.
Counterfeit tramadol tablets are a documented concern in West Africa and the Middle East, where tablets may contain incorrect doses, no tramadol at all, or undisclosed adulterants. Any tablet obtained outside a licensed pharmacy warrants testing — reagent results and fentanyl test strip data provide a starting point but do not guarantee purity or accurate dosing.
Guidelines
- Start with the lowest effective dose and wait at least 2 hours before considering redosing — extended-release formulations require even longer.
- Never exceed 400 mg in 24 hours (the maximum recommended therapeutic dose).
- Do not crush or chew extended-release tablets — this defeats the slow-release mechanism and delivers the full dose at once.
- Test any tablet obtained outside a licensed pharmacy with reagent kits and fentanyl test strips.
- Stay hydrated and eat before dosing — tramadol-associated low blood sugar is a documented risk.
- Do not drive or operate machinery. The stimulant component can mask sedation.
- If taking any antidepressant, anti-anxiety medication, or other opioid, consult the Drug Interactions section before use.
Set & Setting
Tramadol's effects are shaped by individual metabolism more than by psychological set, but context still matters. First-time use is safest in a comfortable environment with a trusted person present — seizure risk means sudden loss of consciousness is possible at higher doses.
The stimulant-like component can create a false sense of sobriety, making driving and other dangerous activities feel safe when opioid impairment is still present. Sedation may deepen for hours as M1 accumulates.
Aftercare & integration. After tramadol use, prioritize sleep, hydration, and nutrition. Residual effects can persist well beyond the perceived end of the experience, as M1 remains active for hours. Avoid operating vehicles or making important decisions for at least 12 hours after the last dose.
If tramadol was used for non-medical purposes, honest self-assessment of motivation and frequency is valuable. Escalating dose, increasing frequency, or using tramadol to manage mood rather than pain are early indicators of problematic use.
Recovery & Support
Tramadol withdrawal combines classic opioid symptoms with atypical serotonergic features — hallucinations, unusual sensory disturbances, excessive mucus. Tapering should be medically supervised. Abrupt discontinuation is not recommended.
Medical providers familiar with opioid tapering may not recognize the serotonergic withdrawal component. Communicating the dual nature of tramadol dependence to treatment providers is important. Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction medicine services, and opioid-focused peer support groups.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seizures (uncontrolled shaking, loss of consciousness), slowed or stopped breathing, blue or grey lips, unresponsiveness, rigid muscles with high fever and rapid heartbeat (signs of serotonin syndrome), or confusion with extreme drowsiness.
Immediate steps:
- 1. Call emergency services immediately if someone is seizing, not breathing normally, or unresponsive.
- 2. If breathing has slowed or stopped, administer naloxone if available — it partially reverses tramadol's opioid effects.
- 3. Place an unconscious but breathing person in the recovery position (on their side, head tilted back).
- 4. If a seizure occurs, clear the area of hard objects. Do not restrain the person or place anything in their mouth.
- 5. Do not induce vomiting.
What to tell the dispatcher: The substance taken (tramadol), approximate amount, time of ingestion, and current symptoms. Many jurisdictions have Good Samaritan laws that protect callers from prosecution.
Reversal agents: naloxone partially reverses tramadol's opioid effects but does not address seizures or serotonin syndrome. These complications require medical intervention.
Legal Status[edit]
Tramadol occupies an unusual position in drug law — despite documented misuse and abuse liability, it remains outside the international narcotic control framework established by the UN 1961 and 1971 conventions.[13]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Reclassified from unscheduled to Schedule IV in August 2014. Maximum 5 refills per 6-month period.[4] |
| United Kingdom | Class C, Schedule 3 controlled drug | Reclassified June 2014. Exempt from safe custody requirement.[10] |
| Canada | Schedule I (Narcotic Control Regulations) | Added 2021 following evidence of contribution to 18+ deaths (2006–2017).[3] |
| Australia | Schedule 4 (Prescription Only) | Added to SafeScript real-time monitoring from July 2023. Not classified as Schedule 8.[31] |
| EU member states | Prescription only (varies by country) | Listed in national pharmaceutical registries. Not under UN narcotic conventions.[13] |
| International | Not under international control | INCB Alert 7 (2018) raised concerns about non-medical use but tramadol remained outside UN 1961/1971 schedules.[13] |
Legal status changes frequently and varies by jurisdiction. The information above reflects publicly available sources and is not legal advice. Verify current local regulations before possession or use.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- —
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- codeine · morphine · oxycodone
Toxicity
Tramadol has lower acute toxicity than classical opioids at therapeutic doses,[9] but three dose-limiting risks narrow its safety margin.
Seizures
Tramadol lowers the seizure threshold in a dose-dependent manner.[8] Risk is significantly elevated in people with epilepsy or other conditions that lower seizure threshold. Tramadol-induced seizures occur through a mechanism independent of brain serotonin levels.[5]
Respiratory Depression
Less severe than morphine at equivalent analgesic doses but clinically significant in overdose.[1] Benzodiazepine co-administration presents a specific paradox: it abolishes tramadol-induced seizures but worsens respiratory depression by reducing breathing volume.[5]
Serotonin Syndrome
Life-threatening serotonergic toxicity is documented when tramadol is combined with SNRIs,[25] gabapentin,[26] MAOIs, tricyclic antidepressants, SSRIs, and ziprasidone.[27] Serotonin syndrome has also occurred from tramadol alone in a pediatric patient without concurrent serotonergic drugs.[28] Among opioids, only tramadol and meperidine trigger serotonin syndrome-like responses in SERT-deficient animal models.[29]
Hypoglycemia
Analysis of over 12 million FDA adverse event reports identified significantly increased low blood sugar with tramadol compared to other opioids.[23] The mechanism is unknown.[24]
Cardiovascular Effects
Tramadol's serotonin- and norepinephrine-raising mechanism raises theoretical concerns for vasoconstriction and cardiovascular events.[30] Controlled data are limited.
CYP2D6 Ultrarapid Metabolizer Toxicity
In CYP2D6 ultrarapid metabolizers, standard doses produce excessive M1, resulting in opioid toxicity — slowed breathing, extreme sedation, and confusion. At least one pediatric death has been reported. FDA labeling now contraindicates tramadol in known ultrarapid metabolizers.[6]
Pediatric Toxicity
Tramadol is contraindicated in children under 12 and in all patients under 18 for post-tonsillectomy or adenoidectomy pain suppression. Life-threatening respiratory depression and death have occurred in pediatric patients.[6]
Psychological Risks
Tramadol's psychological risk profile combines opioid and antidepressant-class elements. Psychological dependence is moderate compared to stronger opioids,[22] though significant misuse is documented in Iran, Egypt, and sub-Saharan Africa, where tramadol is a primary drug of abuse.[11][12]
The SNRI component produces mood disturbance on discontinuation that extends beyond typical opioid withdrawal.[7] Case reports document undetected tramadol dependence in adolescents treated for non-cancer pain,[31] highlighting underrecognition of abuse risk in younger populations.
Tolerance & Dependence
Early reviews reported minimal tolerance development in therapeutic use.[1] Contemporary experience indicates that tolerance does develop with prolonged use, particularly at high doses, involving both opioid receptor adaptation and monoamine system changes.
Physical dependence develops with regular use.[12] Tramadol withdrawal presents as a dual syndrome[7]:
- Classic opioid withdrawal: anxiety, sweating, insomnia, muscle pain, gastrointestinal distress.
- Atypical serotonergic withdrawal: Excessive mucus production, chest fullness, unusual sensory phenomena, and hallucinations — symptoms not seen with conventional opioid cessation.
Psychological dependence is moderate relative to Schedule II opioids. European data confirm lower drug liking.[22] Specific tolerance kinetics — how quickly tolerance develops and how long it takes to reset — have not been characterized.citation needed
Drug Interactions
Tramadol's dual mechanism creates an unusually broad interaction profile.
Serotonin syndrome. Co-administration with any serotonin-raising drug risks serotonin syndrome. Documented combinations include SNRIs,[25][32] gabapentin,[26] ziprasidone,[27] MAOIs, tricyclic antidepressants, SSRIs, and serotonin precursors (5-HTP, tryptophan). Among opioids, only tramadol and meperidine carry this risk — morphine does not.[29]
CNS depressant synergy. Combination with benzodiazepines, alcohol, other opioids, or GHB/GBL produces additive respiratory depression. The tramadol-benzodiazepine combination carries a specific paradox: benzodiazepines abolish tramadol-induced seizures but worsen respiratory depression.[5]
CYP2D6 inhibitors. Potent CYP2D6 inhibitors (paroxetine, fluoxetine, duloxetine) reduce M1 formation — diminishing opioid analgesia — while increasing tramadol plasma levels and serotonergic exposure.[33]
Seizure threshold drugs. Stimulants (amphetamine, cocaine, MDMA) and tramadol both lower seizure threshold. Combined use may trigger seizures, compounded by cardiovascular strain.
Contraindications
10 knownAbsolute:
- MAOIs (current or within 14 days): Severe or fatal serotonin syndrome may result.[1]
- CYP2D6 ultrarapid metabolizer status: Excess M1 causes opioid toxicity at standard doses.[6]
- Children under 12: Life-threatening respiratory depression and death reported.[6]
- Post-tonsillectomy/adenoidectomy in patients under 18: Specific FDA contraindication.[6]
Relative:
- Epilepsy or lowered seizure threshold: Tramadol's proconvulsant activity makes it inappropriate for seizure-prone individuals.[8]
- Concurrent serotonergic medication: SSRIs, SNRIs, tricyclic antidepressants, triptans, and serotonin precursors increase serotonin syndrome risk.[25][26]
- Severe liver impairment: Tramadol's dependence on liver metabolism means impaired function alters drug and metabolite exposure unpredictably.
- Pregnancy: Misuse in pregnancy is associated with neonatal withdrawal syndrome.[34]
- Breastfeeding in CYP2D6 ultrarapid metabolizer mothers: Excess M1 in breast milk poses risk to nursing infants.[35]
- Concurrent CNS depressants: Alcohol, benzodiazepines, other opioids — enhanced respiratory depression.[5]
Harm Reduction[edit]
Forms & Identification
Tramadol circulates almost exclusively as pharmaceutical tablets and capsules in both immediate-release and extended-release formulations. In regulated markets, prescription tramadol from licensed pharmacies carries lower identification risk than most illicitly sourced substances.
Counterfeit tramadol tablets are a documented concern in regions with high non-medical use, particularly West Africa and the Middle East, where tablets may contain incorrect doses, no tramadol at all, or undisclosed adulterants. Any tablet obtained outside a licensed pharmacy warrants testing — reagent results and fentanyl test strip data shown above provide a starting point, but they do not guarantee purity or accurate dosing.
Guidelines
- Start with the lowest effective dose and wait at least 2 hours before considering redosing — extended-release formulations require even longer.
- Never exceed 400 mg in 24 hours (the maximum recommended therapeutic dose).
- Do not crush or chew extended-release tablets — this defeats the slow-release mechanism and delivers the full dose at once.
- Test any tablet obtained outside a licensed pharmacy with reagent kits and fentanyl test strips.
- Stay hydrated and eat before dosing — tramadol-associated low blood sugar is a documented risk.
- Do not drive or operate machinery. The stimulant component can mask sedation.
- If you take any antidepressant, anti-anxiety medication, or other opioid, consult the Drug Interactions section before use.
Set & Setting
Tramadol's effects are modulated by CYP2D6 genotype more than by psychological set, but context still matters. First-time users should be in a comfortable, safe environment with a trusted person present, particularly because seizure risk means sudden loss of consciousness is possible at higher doses.
The stimulant-like component can create a false sense of sobriety, leading to driving or other dangerous activities while opioid impairment is still present. Sedation may deepen as the longer-lasting M1 metabolite accumulates over hours.
Aftercare & integration. After tramadol use, prioritize sleep, hydration, and nutrition. The extended duration of M1 means residual effects can persist well beyond the perceived end of the experience. Avoid operating vehicles or making important decisions for at least 12 hours after the last dose.
If tramadol was used for non-medical purposes, honest self-assessment of motivation and frequency is valuable. Escalating dose, increasing frequency, or using tramadol to manage mood rather than pain are early indicators of problematic use patterns.
Recovery & Support
Tramadol dependence produces a withdrawal distinct from other opioids — classical opioid withdrawal symptoms combined with atypical serotonergic features (hallucinations, unusual sensory disturbances, excessive mucus) means tapering should be medically supervised. Abrupt discontinuation is not recommended.
Medical providers experienced with opioid tapering may not anticipate the serotonergic withdrawal component. Communicating the dual nature of tramadol dependence to treatment providers is important. Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction medicine services, and opioid-focused peer support groups.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seizures (uncontrolled shaking, loss of consciousness), slowed or stopped breathing, blue or grey lips, unresponsiveness, rigid muscles with high fever and rapid heartbeat (signs of serotonin syndrome), or confusion with extreme drowsiness.
Immediate steps:
- 1. Call emergency services immediately if someone is seizing, not breathing normally, or unresponsive.
- 2. If breathing has slowed or stopped, administer naloxone if available — it partially reverses tramadol's opioid effects.
- 3. Place an unconscious but breathing person in the recovery position (on their side, head tilted back).
- 4. If a seizure occurs, clear the area of hard objects. Do not restrain the person or place anything in their mouth.
- 5. Do not induce vomiting.
What to tell the dispatcher: The substance taken (tramadol), approximate amount, time of ingestion, and current symptoms. Many jurisdictions have Good Samaritan laws that protect callers from prosecution.
Reversal agents: naloxone partially reverses tramadol's opioid effects but does not address seizures or serotonin syndrome. These complications require medical intervention.
Legal Status[edit]
Tramadol occupies an unusual position in international drug law. Despite documented misuse and abuse liability, it remains outside the international narcotic control framework established by the UN 1961 and 1971 conventions. The International Narcotics Control Board issued Alert 7 in 2018 highlighting growing global non-medical use, yet tramadol was not internationally scheduled.[13]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Reclassified from unscheduled to Schedule IV in August 2014. Maximum 5 refills per 6-month period.[4] |
| United Kingdom | Class C, Schedule 3 controlled drug | Reclassified June 2014. Exempt from safe custody requirement.[10] |
| Canada | Schedule I (Narcotic Control Regulations) | Added 2021 following evidence of contribution to 18+ deaths (2006–2017).[3] |
| Australia | Schedule 4 (Prescription Only) | Added to SafeScript real-time monitoring from July 2023. Not classified as Schedule 8.[36] |
| EU member states | Prescription only (varies by country) | Listed in national pharmaceutical registries. Not under UN narcotic conventions.[13] |
| International | Not under international control | INCB Alert 7 (2018) raised concerns about non-medical use but tramadol remained outside UN 1961/1971 schedules.[13] |
The regulatory asymmetry — Schedule IV in the US, Schedule I narcotic in Canada, prescription-only in much of Europe, and uncontrolled internationally — reflects divergent national assessments of tramadol's abuse liability and public health impact.
Frequently asked questions
What is Tramadol?
Tramadol is a synthetic centrally acting opioid analgesic with dual mu-opioid agonist and SNRI activity, first marketed in Germany in 1977. Its clinical effects depend heavily on CYP2D6-mediated conversion to the active metabolite O-desmethyltramadol (M1).
How long does Tramadol last?
Total duration by route of administration — Oral: 6 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Tramadol?
Psychedex publishes a dosage table for Tramadol on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Tramadol?
The highest-severity documented interactions for Tramadol: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Amphetamines (Dangerous), Anticholinergics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Tramadol addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Tramadol: tolerance builds moderate; cross-tolerance develops with codeine, morphine, oxycodone, hydrocodone, heroin, fentanyl, other mu-opioid agonists. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcdefgLagard C, Chevillard L, Malissin I, Risède P, Callebert J, Labat L, Launay JM, Laplanche JL, Mégarbane B (2016) Mechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose? — Toxicology and Applied Pharmacology doi:10.1016/j.taap.2016.09.013
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abcdefgLagard C, Chevillard L, Malissin I, Risède P, Callebert J, Labat L, Launay JM, Laplanche JL, Mégarbane B (2016) Mechanisms of tramadol-related neurotoxicity in the rat: Does diazepam/tramadol combination play a worsening role in overdose? — Toxicology and Applied Pharmacology doi:10.1016/j.taap.2016.09.013
- [6]